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Health) was conducted. SourceLX contains linked prescription
and diagnosis claims for $35 million patients with insurance
coverage from a variety of sources. Data were screened to identify
records between December 1, 2005 and November 30, 2006 with
a medical claim for BoNT-A (UB92 or CMS1500) and an ICD-9
diagnosis for headache or migraine on the same claim.RESULTS:
In the 12-month analysis period, approximately 2.88 million
people visited a physician for headache or migraine. Only 1754
patients (0.06%) received treatmentwith BoNT-A; the vastmajor-
ity (80%) had a speciﬁc diagnosis of migraine, not a general
diagnosis of headache. BoNT A recipients were between 40–59
years of age (46%) and most were female (83.1%); BoNT-A
treatment was most often (84%) prescribed by a neurologist.
Fewer (26%) BoNT-A treated users compared to non- BoNT-A
users (52%) were using more than one medication to treat head-
ache or migraine symptoms. In BoNT-A users, the use of combi-
nation pain medication (2 of the following: opioid analgesic,
non-narcotic analgesic, topical anesthetic, NSAID or synthetic
narcotic) was signiﬁcantly reduced in the 90 days after BoNT-A
treatment (p < 0.01). CONCLUSION: BoNT-A treated users are
mostly migraine sufferers. BoNT A treated patients required less
pain medication. Further research needs to be conducted to deter-
mine whether BoNT-A impacts overall treatment costs.
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OBJECTIVE: To summarize clinical rates in treating neuropathic
pain of three drug classes: tricyclic antidepressants (TCAs),
serotonin-norepinephrine reuptake inhibitors (SNRIs), and anti-
convulsants (ACs). METHODS: Patients included adults diag-
nosedwith neuropathic pain experienced >3months.We accepted
double-blinded randomized clinical trials using any drug within
these classes against placebo/active comparator. Outcomes re-
ported were pain score changes on a visual analog scale (VAS),
partial response and response (30% and 50% reduction, respec-
tively), and ADR dropout rates. Two independent reviewers
searchedMedline, Embase, and Cochrane databases (inception to
2007), plus references from retrieved articles. Discrepancies were
resolved by consensus (adjudication by a third reviewer). Data
were extracted/veriﬁed similarly. Quality was similarly assessed
using Jadad’s method. Homogeneity of effects was determined
using Chi-square and I-square. Data were combined using a
random-effects model. RESULTS: From 115 articles, 84 were
excluded (45 inappropriate drugs, 20 inappropriate patients, 12
unacceptable designs, ﬁve insufﬁcient outcome data, one dupli-
cate, and one not located), leaving 28. Thirteen studies (N = 1257)
evaluated ACs (gabapentin, pregabalin), ﬁve SNRIs (N = 781),
and ten TCAs (N = 249). One evaluated both ACs and TCAs.
Quality was 81%  21% overall. Weighted mean baseline-
endpoint VAS differences were: TCAs = 1.8 (95%CI = 1.2–2.4;
13 studies, N = 249), SNRIs = 2.7 (95%CI = 2.4–3.0; 10 studies,
N = 781), and ACs = 2.4 2 were signiﬁcant and I2 were c
(95%CI = 2.0–2.8; 20 studies, N = 1257). All 63%–90%, indi-
cating heterogeneity. For partial response, we analyzed 17 study
arms (N = 1439), nine involving ACs (n = 870), four examining
SNRIs (n = 458), and four that studied TCAs (n = 111). Rates
were: SNRIs = 66.0%  2.2%, ACs = 54.5%  3.7%, and
TCAs = 49.2%  6.6%. For full response, 27 study arms were
summarized: SNRIs = 45.9%  2.3%, ACs = 36.3%  3.2%,
and TCAs = 32.3%  4.4%. ADR dropout rates were:
ACs = 12.3%  1.8% (N = 1,259), SNRIs = 12.0%  2.3%
(N = 732), TCAs = 11.7%  2.7% (N = 267). CONCLUSION:
For all success measures, SNRIs rates were highest, then ACs, then
TCAs. Dropout rates were comparable among drug classes.
PSY2
THE DEVELOPMENT OF A STANDARDIZED CLINICAL
ALGORYTHMIC PREDICTOR OFWEIGHT LOSS AFTER
BARIATRIC SURGERY: DATABASE ANALYSIS ENABLES
EMPIRICAL AND STATISTICAL PREDICTION OFTHRESHOLD
WEIGHT LOSS BY END OFTHIRD POST-OPERATIVE
PHYSICIANVISIT
Hayward A1, Roggenbach MMW1, Purdy C1, Einarson TR2,
Iskedjian M1
1PharmIdeas, Buffalo, NY, USA, 2University of Toronto,Toronto, ON,
Canada
OBJECTIVE: To use clinician reported data pre- and post-
operative in bariatric surgery patients to create an algorithm for
the development of a standardized tool, for use by bariatric
surgeons within a conﬁdence interval, to determine the
maximum weight loss threshold from roux en y surgery by the
third physician visit. METHODS: Retrospective database
analysis (2000–2007) of empirical clinical data, pre- and
post-operative, for bariatric patients in Western New York. A
multivariate model examined the relationship between % excess
body weight lost (BWL) at the ﬁrst three post-operative visits and
% BWL at the sixth post-operative visit (V6), using SAS 9.1.
Percent excess BWL was plotted vs. days elapsed from surgery.
179 obese adults (women = 155, 86.6%) received gastric bypass
surgery, mean BMI = 53, (SD = 9.6), mean excess body weight at
time of procedure = 185 lbs (SD = 65.3). RESULTS: Outcomes
were available for 158 patients (women = 137, 86.7%) at V6
(mean = 707 days), mean BMI = 35.2 (SD = 7.7), women = 34.7
vs. men = 38.1. Mean % excess BWL at V6 was 60%
(SD = 18%). Women had more BWL than men (61% vs. 55%).
For females, BWL was maximized at 870 days post-operation,
the equation ﬁt for males did not yield an absolute maximum,
leveling off at 740 days (monthly change rate < 0.5%/month).
Our model included linear and non-linear components to corre-
late the relationship between the total % excess BWL at V6 and
% excess BWL at the ﬁrst three visits. All variables, except BWL
at the second visit, were statistically signiﬁcant. The algorithm
had a predictive accuracy of 94%. CONCLUSION: The excess
BWL at the third visit is predictive of the ﬁnal excess BWL,
following surgery. Gender and initial BMI displayed signiﬁcant
relationships with ﬁnal weight loss. The algorithm derived from
this sample will support the development of a standardized tool
to assist physicians in their post-operative prognosis of gastric
bypass patients.
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OBJECTIVE: To assess the ability of BTX-A injections to lower
migraine frequency in chronic sufferers. METHODS: Two re-
viewers independently searched PubMed, Google Scholar and
Cochrane Library to locate randomized, double-blind, placebo-
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controlled trials of BTX-A for chronicmigraines. Differences were
settled via consensus. Data extraction/veriﬁcation were managed
similarly. The primary outcome was baseline-endpoint change in
migraine frequency (number/month). Heterogeneity was assessed
using c2 and I-squared. Two raters assessed study quality using the
Downs-Black scale, with adjudication via consensus. A ﬁxed-
effects model combined study results using the standardized mean
difference (Cohen’s d) in monthly migraine frequency between
placebo and BTX-A groups. RESULTS: Nine trials (N = 2114;
BTX-A = 1388, placebo = 726; 2059 completed their trials) pro-
vided data in 19 study arms and 9 placebo arms. The average age
was 43 +/- 3, duration of illness was 20 +/- 3 years, average
number of migraines was 6.0 +/- 2.1/month, 84% were females.
All c2 were non-signiﬁcant; all I-suared were 0, suggesting com-
binability and conﬁrmed using a ﬁxed-effects model. Quality
scores averaged 67% +/- 4% (“fair”; range:62%–75%). The
weighted average treatment effect (Cohen’s d) of BTX-A over
placebo was -0.05 (CI95% = -0.13, 0.03) when measured 30
days after injection, -0.04 (CI95% = -0.12, 0.04) at 60 days, and
-0.04 (CI95% = -0.12, 0.04) at 90 days post-injection. Two
comparisons out of 57 were signiﬁcant; one by Relja after 60 days
and one by Vo after 90 days. Controlling for placebo effect and
stratifying by dose stratiﬁcation found no signiﬁcant effect of
BTX-A in reducting migraine frequency per month over saline
vehicle. CONCLUSION: BTX-A used as prophylactic treatment
of chronic migraine headaches does not decrease monthly
numbers of migraines.
PSY4
THE BALANCE BETWEEN SEVERE CARDIOVASCULAR AND
GASTROINTESTINAL EVENTS AMONG USERS OF SELECTIVE
AND NON-SELECTIVE NON STEROIDAL
ANTI-INFLAMMATORY DRUGS
Van der Linden MW1,Van der Bij S2,Welsing P3, Kuipers E4,
Herings RM5
1PHARMO Institute for Drug Outcomes Research, Utrecht,
Netherlands, 2PHARMO Institute, Utrecht, Utrecht, Netherlands,
3Pﬁzer BV, Capelle a/d Ijssel, ZH, Netherlands, 4Erasmus University
Medical Center, Rotterdam, Netherlands, 5PHARMO Institute,
Utrecht, Netherlands
OBJECTIVE: To simultaneously assess risk of acute myocardial
infarction (AMI), any cardiovascular (CV) and gastrointestinal
(GI) events with traditional non-selective NSAIDs (tNSAIDs)
and COX-2-inhibitors (coxibs). METHODS: Using the
PHARMO Record Linkage System, including drug-dispensing
and hospitalization data of >2 million residents of The Neth-
erlands, subjects with a ﬁrst hospitalization for AMI, any CV,
and GI diagnoses were identiﬁed. NSAID and coxib use was
classiﬁed into remote, recent and current use. Naproxen users
were excluded. Cases were matched to controls in a 1 to 4 ratio
on age and date. Multivariate analyses adjusted for gender,
history of hospitalizations and medications. RESULTS: Com-
pared with remote use, AMI risk was increased among current
users of coxibs combined (adjusted OR 1.63, 95% conﬁdence
interval 1.24–2.16) and among current users of tNSAIDs com-
bined (adjusted OR 1.29, 95% CI 1.08–1.55). AMI risk with
current use of celecoxib (1.63, 1.09 3.54), rofecoxib (1.59,
1.15–2.19), ibuprofen (1.54, 1.13–2.09) and diclofenac (1.43,
1.13–1.82) was signiﬁcantly increased. Risk of any CV event
with current use of celecoxib, rofecoxib, diclofenac and
tNSAIDs other than ibuprofen or diclofenac was signiﬁcantly
increased (adjusted OR ranged from 1.22 to 1.70) . GI risk
with current use of rofecoxib (1.73, 1.27–2.35), ibuprofen
(1.40, 1.00–1.95), diclofenac (4.40, 3.55–5.44) and other
tNSAIDs (2.38, 1.86–3.04), but not celecoxib (1.06, 0.47–2.35)
was signiﬁcantly increased. Compared with current use of
celecoxib, adjusted AMI and CV risk was not signiﬁcantly
increased with current use of individual coxibs and individual
tNSAIDs ,but GI risk was increased with diclofenac (adjusted
OR 4.17, 95% C.I. 1.83–9.51). CONCLUSION: AMI and CV
risk was similarly increased with individual coxibs and
tNSAIDs. Use of diclofenac strongly increased GI risk. Residual
confounding and “channelling” can not be excluded.
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OBJECTIVE: To provide cross-cultural comparisons of health
and behavior in obese individuals. METHODS: We analyzed
data from the 2006 National Health and Wellness Survey, a
cross-sectional Internet-based survey conducted annually in the
United States and EU (FR, DE, UK, SP and IT). When
weighted, the sample is representative of the country’s adult
population in terms of key sociodemographic characteristics.
The survey gathers information regarding demographics, health
conditions, quality of life, and health care use. Adults were
classiﬁed as overweight/obese (OWOB) based on BMI >= 25.
Comparisons between groups were conducted using the Chi-
square test with a signiﬁcance level of p < 0.05. RESULTS:
Almost 70% (144 M) of the United States population is
OWOB, compared to just over half of Europeans (131 M). In
both regions the OWOB populations were typically married
and employed, with a mean age of 48 yrs (USA) and 51 yrs
(EU) (p < 0.05). Both had high rates of cardiovascular
co-morbidities and a family history of obesity or diabetes. The
majority reported having less than very good health and “some/
little/no” energy in the past four weeks. Most had seen a health
care provider in the past six months (82% USA vs. 87% EU;
p < 0.05). Although many claimed to be taking steps to lose
weight (62% US vs. 50% EU; p < 0.05), most reported weight
gain over the past 6 months (30% US vs. 28% EU, p < 0.05).
Only a small portion reported taking a weight-loss prescription
(1.9% US vs. 3.5% EU, p < 0.05); but most of the remainder
would consider taking one (45% US vs. 36% EU, p < 0.05).
CONCLUSION: The obesity problem is more evident in the
United States. Americans exhibit higher rates of obesity at a
younger age but have fewer provider visits and use of prescrip-
tions, suggesting potential solutions to the problem.
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OBJECTIVE: Pain symptoms are common among adults aged
65 and older, but prevalence rates have not been updated to
reﬂect current national data. We assess prevalence among U.S.
adults aged 65 and older with respect to pain (joint, lower
back, neck, severe headaches or migraines) and describe symp-
toms by gender, obesity, and arthritis status. METHODS:
Analysis of nationally representative data collected from adults
aged 65 and older (n = 3810) participating in the National
Health and Nutrition Examination Survey (NHANES) 1999–
2004. RESULTS: Joint pain and lower back pain are the most
frequently reported type of pain, affecting 55% and 38% of
elders, respectively. Women are signiﬁcantly more likely than men
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